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Abstract 
Objectives: After adjuvant or definitive radiation for pancreas cancer, there are limited con-
ventional treatment options for recurrent pancreas cancer. We explored the role of (Stereotactic 
Body Radiotherapy) SBRT for reirradiation of recurrent pancreas Cancer. 
Methods: This is a retrospective study of patients reirradiated with SBRT for recurrent pancreas 
cancer. All patients were deemed unresectable and treated with systemic therapy. Fiducial gold 
markers were used. CT simulation was performed with oral and IV contrast and patients were 
treated with respiratory motion tracking in the CyberknifeTM system.  
Results: 30 patients (17 men and 13 women) with a median age of 67 years were included in the 
study. The median target volume was 41.29cc. The median prescription dose was 25Gy (24-36Gy) 
in a median of 5 fractions prescribed to a mean 78% isodose line. The median overall survival was 
14 months. The 1 and 2 year local control was 78%. The worst toxicity included 3/30(10%) Grade 
III acute toxicity for pain, bleeding and vomiting. There was 2/30 (7%) Grade III long-term bowel 
obstructions. 
Conclusions: SBRT can be a useful and tolerable option for patients with recurrent pancreas 
cancer after prior radiation. 
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Introduction 
Pancreatic cancer is the fourth-leading cause of 
cancer-related mortality in the US (1). The natural 
history of pancreas cancer is characterized by poor 
outcomes at all stages and in patients with advanced 
disease <5 % of pancreatic cancer patients are still 
alive at 5 years from diagnosis (2). Despite advances 
in surgery, radiation therapy and systemic therapy 
most patients succumb to metastatic disease. Even 
after curative resection, prospective randomized ad-
juvant therapy trials have shown local failure rates 
ranging from 39-62%, even in the presence of margin 
negative R0 resection (3–6).  
While local failures may have an impact on sur-
vival, they are also often symptomatic and debilitat-
ing, affecting quality of life. Only a small proportion 
of these patients are amenable for further surgical 
resection (7). In the setting of prior adjuvant radiation 
therapy, systemic therapy would be considered the 
standard; however response rates are poor and is as-
sociated with significant toxicity (8–10). Conventional 
external beam fractionated reirradiation is often fea-
sible, but limited by the tolerance doses of normal 
tissue, making it risky (11). 
An emerging treatment that has been success-
fully used in primary therapy and in the setting of 
reirradiation, due to its conformality and avoidance of 
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normal structures, is Stereotactic Body Radiotherapy 
(SBRT). SBRT has been used as primary treatment for 
locally advanced pancreas cancer (12–19). As 
dose-limiting structures restrict reirradiation with 
conventional radiation, SBRT can be useful due its 
conformality in minimizing dose to critical normal 
structures around the tumor. SBRT reirradiation has 
been successfully used in Lung, Head and Neck, 
Spine and other cancers (20–23). 
We report our experience in the use of SBRT for 
reirradiation for unresectable recurrent pancreatic 
cancer treated with prior radiation. 
Materials and Methods 
Patients and Lesions 
Our institutional IRB approved database 
(DFHCC 09-451) was retrospectively reviewed. Pa-
tients treated with SBRT for recurrence after prior 
radiation for adenocarcinoma of the pancreas were 
included in this study. All patients were staged to 
exclude metastatic disease with a CT Torso. Clinical, 
radiological and biochemical (CA19-9) criteria were 
used to identify local recurrence and biopsy or PET 
scans were not mandated. Increase in size of local 
tumor in two dimensions or two consecutive eleva-
tions in CA19-9 with no demonstrable metastasis in 
torso CT staging and a positive PET scan when done 
were used to define local recurrence. All patients were 
systematically reviewed in a multidisciplinary pan-
creatic cancer conference and were deemed unresec-
table. These included patients after prior adjuvant 
radiation following pancreaticoduodenectomy and 
patients with progression after definitive convention-
al or SBRT for locally advanced pancreas cancer. All 
patients received salvage systemic therapy (gemcita-
bine, gemcitabine+nabpaclitaxel or FOLFIRNOX) at 
the discretion of the treating medical oncologist prior 
to and after initiation of the current SBRT study 
treatment.  
SBRT 
All patients who had prior adjuvant radiation or 
prior SBRT at our institution had fiducial gold mark-
ers placed at the time of surgery or under endoscopic 
ultrasound guidance prior to SBRT respectively. 3-5 
gold fiducials were placed in all patients. Patients 
were simulated in supine position with VaclocTM body 
immobilization system. Intravenous and barium con-
trast agent was used for the planning CT. The target 
volume was defined as gross tumor volume (GTV) 
and was contoured on axial CT images. The choice of 
fractionation was based on predetermined criteria 
including tumor volume, location of the tumor and 
prior radiation dose. Other factors, such as interval 
between prior RT, adjacent normal tissue, patients’ 
performance and co morbidity were also taken into 
consideration. The irradiation dose was prescribed to 
the isodose line covering at least 95% of the target 
volume. Maximum point dose to the gastric and du-
odenal walls and the small bowel loops were kept at 
or below prescription dose. We have previously re-
ported the treatment techniques used in this 
study(14,15). Patients were treated on 3-5 consecutive 
days. Prophylactic prochlorperazine, H2 receptor an-
tagonists and simethicone were used before and dur-
ing the treatment.  
Follow up and statistical analysis 
Follow-up data included survival, date of pro-
gression and site of failure at the last follow up. Tu-
mor response to treatment was evaluated by con-
trast-enhanced CT imaging. Local failure was defined 
as an increase in the sum of the longest diameter of 
target lesion. If a new lesion developed in the abdo-
men but outside the radiation field, it was interpreted 
as distant metastasis. Acute and late toxicities were 
defined as symptoms that develop within three 
months after SBRT or later, respectively. Local and 
distant progression rates and the lengths of overall 
survival were calculated from the date of treatment to 
the date of progression or death. The Kaplan-Meier 
method was used for calculating actuarial rates, using 
Graph Pad Prism version 5.00 software for Mac 
(Graph Pad Software, San Diego, CA; Windows; Mi-
crosoft, Seattle, WA). 
Results 
This study included 30 patients reradiated for 
recurrent pancreas cancer at our center between Sep-
tember 2005 and September 2013. 17 males and 13 
females were treated. The median age at the time of 
reirradiation was 67 years (range 44 to 88 years). Me-
dian follow-up was 11 months (4 to 24months). 
Initial stages were as follows: Stage II or I in 
14(48.1%) and Stage III in 16(51.9%). All patients had 
previously received RT, either as part of their initial or 
salvage treatment after they recurred. 25 patients 
were irradiated as part of their initial treatment. 
Among those patients 9 of them underwent SBRT as 
their initial treatment. One patient had whole ab-
dominal radiotherapy (WART) for ovarian cancer 
before she was diagnosed with pancreatic cancer. For 
the patients who were treated with SBRT the prior RT 
median initial dose was 24 Gy in 3 fractions (range, 24 
to 30 Gy) and for patients who were initially treated 
with External Beam Radiation Therapy (EBRT) was 
50.4 Gy (range, 46.8-54 Gy). Time interval between 
initial RT and reirradiation with SBRT ranged from 4 
to 316 months with a median of 18 months. 
Sites of recurrence in previously resected pa-
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tients were the resection bed in 5, celiac or para aortic 
lymph node in 5, resection bed and lymph node in 2 
and remnant pancreas in 1. In locally advanced unre-
sected patients the recurrences were progression in 
the head of the pancreas in 9, body in 3 and celiac 
lymph node in 1. All patients had received initial 
chemotherapy. After recurrence, 14 patients had 
gemcitabine, 6 had FOLFOX and 2 had Erlotinib. 5 
patients did not have additional chemotherapy. 
Tumor volumes ranged from 12.03 to 315.72cc 
(median 41.29 cc). Median prescribed isodose was 
78% (range 60-88%). Total SBRT dose ranged from 24 
to 36 Gy (median 25 Gy) in 3 to 5 fractions (median 5). 
Median conformality and heterogeneity indices were 
1.23 and 1.28 respectively. 
The patient and treatment characteristics are 
listed in Table 1. A representative treatment Plan is 
shown in Figure 1. 
Outcomes 
The overall median survival after reirradiation 
for recurrence was 14 months. The actuarial local 
progression free survival rate was 78%. Four patients 
had only local progression, 6 had distant progression 
and 2 patients had both local and distant progression. 
Among the 8 patients with distant progression 3 had 
liver, 4 had peritoneal and 1 had lung metastasis. The 
actuarial 1-year and 2-year survival rates were 50% 
and 5% respectively. The 1-year and 2-year local con-
trol rates were 78%. Kaplan Meir survival curves for 
Local Control and Overall Survival are shown in Fig-
ure 2.  
 
Table 1: Patient and Treatment Characteristics 
Patient and Treatment Characteristics. number 
Age (Range) 67 (44-88) 
Sex(m/f) 17/13 
Time interval to reirradiation (months) 18 (4-316) 
Initial Treat-
ment 
Surgery + adjuvant Chemoradiation 9 (30%) 
Induction chemotherapy +SBRT 10 (33.3%) 
Definitive Chemoradiation 4 (13.3%) 
Neoadjuvant Chemoradiation +surgery 1(3.3 %) 
Surgery + Adj Chemo + salvage 
chemoradiation 
3 (10%) 
Radiotherapy 1 (3.3%) 
Surgery+ salvage Chemoradiation 2(6.7%) 
SBRT Reirra-
diation 
Treatment volume 41.29cc 
(12.03-315.72) 
Prescribed isodose 78% (60-88) 
Total SBRT dose 25 (24-36) 
No of fractions 3 (3-5) 
Max dose 32,47 (29,27-40) 
Conformality Index 1,23 (1,14-1,66) 
Heterogeneity Index 1,28 (1,14-1,67) 
 
 
 
Figure 1: Representative Treatment Plan 
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Figure 2: Local Control (Top Panel) and Overall Survival (Bottom Panel) 
 
Toxicity 
Treatment was well tolerated in the majority of 
patients. Sixteen patients (60%) reported fatigue and 
four (15%) reported nausea in the first four weeks of 
treatment. Two patients were hospitalized; one for 
gastroduodenal bleeding and vomiting and one pa-
tient was hospitalized for pain (3/27; 11% Grade III 
acute Toxicity). There were 2 late Grade 3 GI compli-
cations (7% Late Grade III Toxicity). Both patients 
developed bowel obstruction that resolved with con-
servative management not requiring surgery. Both 
patients were treated with SBRT as their previous 
treatment and both were under gemcitabine chemo-
therapy when the obstruction occurred. The time in-
terval between the treatments was 23 and 42 months. 
Two other patient developed sub-acute ascites and 
both had negative cytology for malignant cells with-
out any other evidence of progression. 
Discussion 
Management of recurrent pancreatic cancer is 
challenging (24). Therapeutic options are limited, 
particularly after prior radiation therapy. We report 
the utility of SBRT for reirradiation of locally recur-
rent pancreas cancer after prior radiation, with rea-
sonable local control and modest survival. 
While distant failure with or without local re-
currence is a common after definitive local therapy for 
pancreas cancer including surgery (25,26), there exists 
a subgroup of patients who develop isolated local 
recurrence without evidence of distant failure 
(4,27,28). Moreover, patients with isolated local re-
currence after prior definitive local therapy appear to 
do better than patients with initially unresectable 
disease (29) or metastatic disease (30). This suggests 
patients may benefit from additional local therapy if 
feasible and safe. The NCCN (National Comprehen-
sive Cancer Network) guidelines suggest that these 
patients be preferably treated as a part of clinical tri-
als.  
Surgery is not often feasible because of the extent 
of disease, prior radiation therapy and the poor per-
formance status of these patients. In the largest series, 
Kleef et al for University of Heidelberg reported a 
series of 30 patients who underwent surgical explora-
tion for recurrent pancreas cancer (31). Six patients 
had received prior radiation. Fifteen patients were 
able to undergo resection with 8 patients having 
R0/R1 resection. The remaining 15 patients had ex-
ploration and bypass. In addition, 8 patients who did 
not have prior adjuvant radiation received IORT (In-
tra Operative Radiation Therapy). The overall sur-
vival in these patients who were reoperated was 11.4 
months. Patients who were able to undergo resection 
did better (medial overall survival 17 vs. 9.4 months). 
In addition patients with longer disease free interval 
from initial surgery appeared to do better. They also 
reported 1 postoperative death and postoperative 
morbidity in 5 patients. Zacharias et al from Stras-
bourg reported on 15 laparotomies for recurrent pan-
creas cancer (32). The perioperative mortality was 
20%; the post-operative morbidity was 40% and the 
median survival was 7.4 months. Our series of pa-
tients, who all received prior definitive radiation, 
compares well to selected patients undergoing repeat 
laparotomy and able to achieve resection. 
After initial surgery and no post-operative radi-
ation, Chemoradiation is a viable option for isolated 
local recurrences. Wilkowski et al utilized 45 Gy 
3D-conformal radiation therapy with concurrent 
chemotherapy (continuous infusion 5FU, gemcitabine 
or cisplatinum) in 18 patients with isolated local re-
currences (33). They reported 80% response rate with 
a 35% complete response, 37.5 % partial response and 
25% with stable disease. The median progression free 
survival was 14.7 months and the median overall 
survival was 17.5 months. There was no grade 3 or 4 
gastrointestinal toxicity. Similarly, Nakamura and 
colleagues used 54 Gy EBRT with concurrent gem-
citabine or S1 (11). The 1-year overall survival, local 
control, and progression-free survival rates were 69%, 
67%, and 32%, respectively. The median overall sur-
vival and progression-free survival rates were 15.9 
and 6.9 months. 
In the setting of prior adjuvant or definitive RT, 
systemic therapy is often considered the standard of 
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care for local recurrence when reoperation is not fea-
sible or safe (9,8,10,34). Reirradiation with conven-
tional EBRT carries significant risk for morbidity and 
mortality due to dose limiting toxicity from prior ra-
diation. In this series we have explored the role SBRT 
as additional local therapy in this setting.  
Stereotactic Body Radiotherapy (SBRT) has been 
successfully used in the primary therapy and in the 
setting of reirradiation for a variety of cancer sites due 
to its conformality and avoidance of normal structures 
(13–15,20). Additionally, short courses of SBRT allow 
for standard of care chemotherapy regimens to be 
administered without interruption.  
SBRT has been shown to be feasible after con-
ventional EBRT as a planned boost to intensify local 
therapy for pancreatic cancer, particularly in the lo-
cally advanced unresectable setting and for positive 
margins. A study from Stanford included 19 patients 
who were treated with a protocol of 45 Gy intensi-
ty-modulated radiation therapy (IMRT) with concur-
rent 5-FU chemotherapy followed by a 25 Gy SBRT 
boost in one fraction to the primary tumor (35). Six-
teen patients completed the planned therapy. Four 
patients experienced grade 2 toxicity and 2 patients 
experienced grade 3 toxicity. Fifteen of these 16 pa-
tients were free from local progression until death. 
Median overall survival was 33 weeks. They reported 
a high local control rate of 94% but with the accom-
panying toxicity and high systemic failure rates. Sim-
ilarly Seo et al reported a retrospective series of 30 
patients treated with a similar strategy involving 
conventional EBRT for total dose of 40 Gy delivered in 
20 fractions followed by a single fraction of 14, 15, 16, 
or 17 Gy SBRT administered as a boost without a 
break (36). Twenty-one patients received chemother-
apy. Five patients were lost to follow-up. Local pro-
gression only was identified in 3 of the 25 (12%), and 
both local and distant metastasis in 8 of the 25 (32%). 
Of the 30 patients, 20 (66.7%) exhibited Grade 1 or 2 
acute toxicity (nausea, vomiting, and/or pain) for a 
short period. One patient required bypass surgery 
because of the development of a duodenal obstruction 
3 months after SBRT treatment. 
Two other series have reported the utility of 
SBRT after prior definitive EBRT. The University of 
Pittsburgh has reported a series of 71 patients who 
had undergone SBRT for locally advanced pancreas 
cancer. Fifteen of these patients were receiving SBRT 
in the reirradiation setting after a median prior EBRT 
dose of 45 Gy. The median SBRT dose was 24 Gy 
(18-25 Gy), given in a single fraction for 67 patients 
and fractionated in 4 patients. The outcomes of pa-
tients who were reirradiated were not reported sepa-
rately (19). Lominska et al from Georgetown Univer-
sity reported a series of 28 patients who received 
SBRT after a median prior EBRT dose of 50.4 Gy 
(41.40-70.20Gy) (37). 11 of these patients were treated 
with a hypofractionated boost with SBRT delivered 
within 2 months of completing EBRT. The remaining 
17 patients underwent salvage SBRT after imaging 
demonstrated local recurrence or progression. For all 
patients, median total SBRT dose was 22.5 Gy (20–30) 
with a median dose per fraction being 7 Gy (4–8) and 
median number of fractions being 3 (3–5). They did 
not report outcomes for the two subgroups and the 
outcomes for elective versus salvage SBRT for recur-
rences after prior EBRT is unclear. Overall, 12 of 14 
(85.7%) evaluable patients were free from local pro-
gression. The median overall survival was 5.9 months, 
with 18% survival and 70% freedom from local pro-
gression at one year. Toxicity consisted of one case of 
acute grade 2 nausea/vomiting, and 2 cases of grade 3 
late GI toxicity, one being bowel obstruction and the 
other perforation both of which resolved with con-
servative management. Both patients were treated 
with 21 Gy in three fractions, and had received 50.4 
Gy to the abdomen previously.  
Our series exclusively reports on outcomes in the 
difficult clinical setting of local recurrence after prior 
definitive radiation for pancreas cancer. The median 
survival of 14 months and the local control of 78% 
compares favorably with the previously reported re-
sults in this scenario. Treatment related toxicity is of 
significant concern with reirradiation. The 11% acute 
grade 3 toxicity, with resolution and the eventual 7% 
long term toxicity appears reasonable in this difficult 
situation.  
Conclusion 
SBRT reirradiation for recurrent pancreas cancer, 
due to its conformality and avoidance of dose limiting 
critical structures, seems feasible, effective and toler-
able. Future prospective studies are needed to define 
the role of SBRT reirradiation for local recurrences in 
the setting of systemic therapy. 
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